NZ 596663 Disclosed is the use of a VEGF antagonist in the manufacture of a medicament for treating central retinal vein occlusion (CRVO) in a human by intravitreal administration. The disclosed VEGF antagonist is a protein antagonist, and the medicament is formulated for administration in a method comprising: a) administering three first individual doses of the VEGF antagonist at one month intervals； followed by b) administering a number of second individual doses of the antagonist, wherein the second individual doses are administered less frequently than the first individual doses.
